Actuate Therapeutics, Inc.
ACTU
$7.67
-$0.01-0.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 201.53% | 244.58% | 196.39% | 129.04% | 31.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.82% | -18.11% | -13.87% | -16.72% | -2.67% |
| Operating Income | -9.82% | 18.11% | 13.87% | 16.72% | 2.67% |
| Income Before Tax | 9.48% | 23.86% | 15.32% | 5.79% | -18.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.48% | 23.86% | 15.32% | 5.79% | -18.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.48% | 23.86% | 15.32% | 5.79% | -18.97% |
| EBIT | -9.82% | 18.11% | 13.87% | 16.72% | 2.67% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 92.79% | 94.00% | 93.49% | 87.12% | -8.06% |
| Normalized Basic EPS | 91.64% | 93.62% | 93.49% | 88.96% | 6.74% |
| EPS Diluted | 92.79% | 94.00% | 93.49% | 87.12% | -8.06% |
| Normalized Diluted EPS | 91.64% | 93.62% | 93.49% | 88.96% | 6.74% |
| Average Basic Shares Outstanding | 1,154.73% | 1,170.04% | 1,200.35% | 631.73% | 10.10% |
| Average Diluted Shares Outstanding | 1,154.73% | 1,170.04% | 1,200.35% | 631.73% | 10.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |